X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Helocyte gains patent rights to use CMV-MVA Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-HIV CAR T Cells for the treatment of adults living with HIV.
Lead Product(s): CMV-MVA Triplex
Therapeutic Area: Infections and Infectious Diseases Product Name: CMV-MVA Triplex
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Helocyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2023
Details:
CLD-101 platform, which includes NSC.CRAd-S-pk7, is an allogeneic, “off-the-shelf” therapy comprised of an immortalized NSC line loaded with an engineered oncolytic adenovirus.
Lead Product(s): NSC.CRAd-S-pk7
Therapeutic Area: Oncology Product Name: CLD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Calidi Biotherapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.
Lead Product(s): Bisantrene
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Race Oncology Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 10, 2023
Details:
CYTO-102 to be an off-the-shelf cell therapy that can directly kill cancer cells, broadly stimulate the body’s own endogenous immune system, and enhance tumor killing through generation of a highly effective immune response ultimately leading to improved patient outcomes.
Lead Product(s): CYTO-102,Atezolizumab
Therapeutic Area: Oncology Product Name: CYTO-102
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: CytoImmune Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
City of Hope exclusively licensed patent rights covering Vaxina (CF33) to Imugene Limited, a company developing novel therapies that activate the immune system against cancer. Imugene has given CF33-hNIS the name Vaxinia.
Lead Product(s): CF33-hNIS,Pembrolizumab
Therapeutic Area: Oncology Product Name: Vaxina
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Imugene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
A COVID-19 investigational vaccine COH04S1, elicited neutralizing antibodies against the virus’ spike protein also, produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in Phase 1 clinical trial.
Lead Product(s): COH04S1
Therapeutic Area: Infections and Infectious Diseases Product Name: COH04S1
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: GeoVax Labs
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
MB-101, an IL13Rα2-targeted CAR T cell therapy demonstrate durable complete responses in GBM based on a 54-patient Phase 1 trial, as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency and T cell persistence.
Lead Product(s): MB-101
Therapeutic Area: Oncology Product Name: MB-101
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Mustang Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
OST compounds are natural products derived from plants native of tropical and subtropical America, which have been used in alternative and traditional medicine. At City of Hope, these compounds will undergo pharmacologic and toxicologic testing at specialized laboratories.
Lead Product(s): Plant-derived OST Compounds
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Ostentus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 27, 2022
Details:
The Lancet Oncology study is a proof of principle that targeting KRAS G12C with a small molecule KRAS G12C inhibitor, sotorasib, can lead to tumor shrinkage and meaningful duration of disease control in a patient population that otherwise has very limited treatment options.
Lead Product(s): Sotorasib
Therapeutic Area: Oncology Product Name: Lumakras
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
Mosunetuzumab, First-in-Class therapy, showing deep and durable responses for patients whose lymphoma has relapsed or is no longer responding to currently available therapies.
Lead Product(s): Mosunetuzumab,Atezolizumab
Therapeutic Area: Oncology Product Name: BTCT4465A
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
